- 270 million subscribers worldwide with TV functionality on their mobile phones by 2009 estimate visiongain
According to the latest visiongain report "Mobile TV: Market Analysis and Forecasts 2004-2009", Mobile phones and broadcast television are two of the most influential and popular consumer technologies of the electronics age. The merging of the mobile technology and broadcasting television has produced Mobile TV. - visiongain
- VODAFONE: AN INDEPENDENT CONFERENCE - B2B Conferences
Attend the visiongain's b2b conference, VODAFONE: AN INDEPENDENT CONFERENCE - A PARTNER, COMPETITOR AND FUTURE ASSESSMENT. A unique conference where representatives of the wireless industry will gather to discuss Vodafone's successful business models, future ambitions and how the competitors differ. - visiongain
- WIRELESS SERVICES IN IRAQ - B2B Conferences
Attend the visiongain's b2b conference, WIRELESS SERVICES IN IRAQ - OPPORTUNITIES FOR WIRELESS COMPANIES IN THE DEPLOYMENT OF WIRELESS INFRASTRUCTURE AND SERVICES IN IRAQ. This conference’s objective is to provide a unique forum to discuss the technical, financial and logistical challenges to deploy wireless services in Iraq. - visiongain
- Wireless Sport Telecom Conference 2005 - B2B Conferences
Attend visiongain's b2b conference, WIRELESS SPORT: EXPLORING FUTURE BRANDING AND REVENUE-GENERATING OPPORTUNITIES WITH SPORT IN WIRELESS, a unique conference where the mobile industry and the sports world meet to discuss content and branding partnerships. Key representatives from the sports world and mobile industry will gather at this unique venue at Chelsea Village, home ground of the Chelsea Football team. - visiongain
- SMS in the U.S. - The Right Technology for Cellular Messaging Success?
According to the latest visiongain report "SMS in the U.S. - The Right Technology for Cellular Messaging Success?" text Messaging, or SMS, has been hugely successful in many parts of the world, but not so in the United States. The report question why this is and debates whether SMS ever be as popular in the U.S. market compared with the rest of the world. - visiongain
- Visiongain predicts that SavaJe could take a 17 per cent share of the middle level handset market by 2009
According to the latest visiongain report "SavaJe - Challenging the Mobile Operating Market", the mobile handset market operating system market has evolved rapidly in the last 3 years as handsets become increasingly sophisticated. SavaJe (pronounced savage - the name is an comes from of Java SE) is one of a handful of companies hoping to compete in the market which is currently dominated by Symbian, with Microsoft also vying for control. - visiongain
- visiongain reports "World missile market is worth $100 billion until 2012"
A new report published by visiongain entitled " Sea Strike Weapon" forecasts the future of modern warfare as light mobile troops operating independently in littoral areas. The US military is spiraling its capabilities towards sea based warfare during the first quarter of the 21st century and other western forces are readying themselves for littoral warfare. Therefore an increasing need for a suite of defensive weapons systems that can simultaneously defend both sea based assets and amphibious forces. - visiongain
- Anti-Migraine Therapies 2005 B2B Conferences
Attend the visiongain's b2b conference, ANTI-MIGRAINE THERAPIES 2005: IMPROVING DISEASE UNDERSTANDING, DRUG DELIVERY AND FUTURE TARGETS. This conference's objective is to provide a unique forum to discuss the new developments in significant areas of the anti-migraine therapies market. This includes new research data to innovations in drug delivery to future targets for drugs. - visiongain
- visiongain predicts by 2009 Orphan drugs will grow to be worth almost $65 billion
According to the latest visiongain report "Orphan Drugs: Future Directions for a High Growth Market 2004-2009", in 1983 there were just 10 orphan drugs available to treat rare diseases. However in the space of 20 years there are now 210 different drugs resulting in a market that is worth more than $27 billion today. The high cost of orphan drugs and lack of competition in the market means that the industry is extremely profitable for many drugs. - visiongain